Prior to the FDA action, patients were required to get an infusion of rituximab the first day, followed by a pre-treatment diagnostic dose of radiolabeled indium-111 Zevalin.

FORBES: Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer Treatments